Literature DB >> 29959222

Nucleosome Positioning and Gene Regulation of the SGLT2 Gene in the Renal Proximal Tubular Epithelial Cells.

Hiroaki Takesue1, Takeshi Hirota1, Mami Tachimura1, Ayane Tokashiki1, Ichiro Ieiri2.   

Abstract

Filtered glucose is mostly reabsorbed by sodium-glucose cotransporter 2 (SGLT2) in the proximal tubules. SGLT2 is predominantly expressed in the human kidney. However, the regulatory mechanisms for SGLT2 gene expression in the human kidney remain unclear. We in this work elucidated the transcriptional regulatory mechanisms for the SGLT2 gene by nucleosome occupancy in the SGLT2 promoter region. Expressions of SGLT2 mRNA and protein were markedly weaker in human kidney-derived HK-2 cells than the human kidney. The nucleosome occupancy level in the SGLT2 promoter region was low in the kidney, but high in HK-2 cells. A treatment with a histone deacetylase inhibitor trichostatin A (TSA) decreased nucleosome occupancy in the promoter region and increased SGLT2 expression levels in HK-2 cells. The upregulation of SGLT2 expression by histone acetylation was accompanied by a higher binding frequency of hepatocyte nuclear factor (HNF) 1α, a transcriptional modulator of SGLT2 in the human kidney, to the promoter region. The transfection of a HNF1α expression plasmid into HK-2 cells resulted in the upregulation of SGLT2 mRNA expression in the presence of TSA, but not in the treatment of dimethylsulfoxide as a control. Nucleosome occupancy in the promoter region was markedly higher in the liver and small intestine than the kidney. Our results indicate that tissue-specific nucleosome occupancy plays an important role in the regulation of SGLT2 gene expression via HNF1α binding at the SGLT2 promoter region.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29959222     DOI: 10.1124/mol.118.111807

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects.

Authors:  Masamitsu Takashima; Kuniyuki Nakamura; Takuya Kiyohara; Yoshinobu Wakisaka; Masaoki Hidaka; Hayato Takaki; Kei Yamanaka; Tomoya Shibahara; Masanori Wakisaka; Tetsuro Ago; Takanari Kitazono
Journal:  Commun Biol       Date:  2022-07-02

2.  Understanding the Mechanism of Dysglycemia in a Fanconi-Bickel Syndrome Patient.

Authors:  Sanaa Sharari; Mustapha Aouida; Idris Mohammed; Basma Haris; Ajaz Ahmad Bhat; Iman Hawari; Sabah Nisar; Igor Pavlovski; Kabir H Biswas; Najeeb Syed; Selma Maacha; Jean-Charles Grivel; Maryam Saifaldeen; Johan Ericsson; Khalid Hussain
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-18       Impact factor: 6.055

3.  Direct evidence of proximal tubular proliferation in early diabetic nephropathy.

Authors:  Noriko Uehara-Watanabe; Natsuko Okuno-Ozeki; Atsushi Minamida; Itaru Nakamura; Tomohiro Nakata; Kunihiro Nakai; Aya Yagi-Tomita; Tomoharu Ida; Kisho Ikeda; Takashi Kitani; Noriyuki Yamashita; Michitsugu Kamezaki; Yuhei Kirita; Satoaki Matoba; Keiichi Tamagaki; Tetsuro Kusaba
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

4.  Proximal tubular epithelia-specific transcriptomics of diabetic mice treated with dapagliflozin.

Authors:  Noriko Uehara-Watanabe; Natsuko Okuno-Ozeki; Itaru Nakamura; Tomohiro Nakata; Kunihiro Nakai; Aya Yagi-Tomita; Tomoharu Ida; Noriyuki Yamashita; Michitsugu Kamezaki; Yuhei Kirita; Satoaki Matoba; Keiichi Tamagaki; Tetsuro Kusaba
Journal:  Heliyon       Date:  2022-09-13

5.  A multigenerational study on phenotypic consequences of the most common causal variant of HNF1A-MODY.

Authors:  Jarno L T Kettunen; Elina Rantala; Om P Dwivedi; Bo Isomaa; Leena Sarelin; Paula Kokko; Liisa Hakaste; Päivi J Miettinen; Leif C Groop; Tiinamaija Tuomi
Journal:  Diabetologia       Date:  2021-12-24       Impact factor: 10.460

Review 6.  HNF1A Mutations and Beta Cell Dysfunction in Diabetes.

Authors:  Yasutaka Miyachi; Takashi Miyazawa; Yoshihiro Ogawa
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.